Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1A/1B PK/PD study assessing TX45 in healthy volunteers

Next Previous
Trial Profile

A Phase 1A/1B PK/PD study assessing TX45 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TX-000045 (Primary)
  • Indications Cardiovascular disorders; Lung disorders
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept

Most Recent Events

  • 17 May 2025 According to a Tectonic Therapeutic media release, topline data from Part B of the Phase 1b study in another type of pulmonary hypertension patients,expected in the second half of 2025.
  • 17 May 2025 According to a Tectonic Therapeutic media release, complete results from Part A(n=19) of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction are being presented in a late-breaking, oral session at the European Society of Cardiology (ESC) Heart Failure 2025 Congress being held in Belgrade, Serbia.
  • 17 May 2025 Results presented in the Tectonic Therapeutic media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top